Related Experiment Video
Updated: Jul 26, 2025

06:38
Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
Published on: December 8, 2023
1.0K
Structural and Biophysical properties of therapeutically important proteins Rv1509 and Rv2231A of Mycobacterium
Nilisha Rastogi1, Sheeba Zarin2, Anwar Alam3
1Cell Signaling and Inflammation Biology Lab, ICMR-National Institute of Pathology, New Delhi 110029, India.
International Journal of Biological Macromolecules
|June 18, 2023
Summary
Two unique Mycobacterium tuberculosis (M.tb) signature proteins, Rv1509 and Rv2231A, were biophysically characterized. Their structure-function insights offer potential for novel anti-TB drug development and diagnostics.
Area of Science:
- Microbiology and Infectious Diseases
- Structural Biology
- Biochemistry
Background:
- Mycobacterium tuberculosis (M.tb) poses a significant global health challenge.
- Identifying unique M.tb proteins is crucial for developing targeted therapeutics.
- Rv1509 and Rv2231A were identified as M.tb-specific signature proteins.
Purpose of the Study:
- To biophysically characterize the M.tb signature proteins Rv1509 and Rv2231A.
- To elucidate the structure-function relationships of Rv1509 and Rv2231A.
- To assess the therapeutic potential of Rv1509 and Rv2231A as drug targets.
Main Methods:
- Comparative sequence analysis using BLASTp and BLASTn.
- Dynamic Light Scattering and Analytical Gel Filtration Chromatography for oligomeric state.
- Circular Dichroism and Fourier Transform Infrared spectroscopy for secondary structure.
- Fluorescence spectroscopy for binding affinity studies.
Main Results:
- Rv1509 exists as a monomer; Rv2231A exists as a dimer in solution.
- Both proteins exhibit stability across a range of temperatures and pH.
- Rv1509 binds iron, potentially aiding M.tb growth; Rv2231A shows Mg2+-dependent RNA binding, suggesting RNase activity.
Conclusions:
- This is the first biophysical characterization of Rv1509 and Rv2231A.
- The findings provide critical structure-function insights into these M.tb signature proteins.
- Rv1509 and Rv2231A represent promising targets for novel anti-tuberculosis drugs and diagnostics.

